Biodegradable stents as a platform to drug loading.
Despite technical and mechanical improvement in coronary stents the incidence of restenosis caused by in-stent neointimal hyperplasia remains high. Oral administration of numerous pharmacological agents has failed to reduce restenosis after coronary stenting in humans, possibly owing to insufficient local drug concentration. Therefore, drug-eluting stents were developed as a vehicle for local drug administration. The authors developed a new drug-eluting polymer stent that is made of poly-l-lactic acid polymer mixed with tranilast, an anti-allergic drug that inhibits the migration and proliferation of vascular smooth muscle cells induced by platelet-derived growth factor and transforming growth factor->1. Polymer stents might be superior to polymer-coated metallic stents as local drug delivery stents in terms of biodegradation and the amount of loaded drug. Drug-mixed polymer stents can be loaded with a larger amount of drug than can drug-coated metallic stents because the polymer stent struts can contain the drug. Clinical application is required to assess the safety and efficacy of drug-eluting polymer stents against stent restenosis.
Tsuji
Takafumi
T
Department of Cardiology, Shiga Medical Center for Adults, Shiga, Japan. tamai@cct.gr.jp
Tamai
Hideo
H
Igaki
Keiji
K
Kyo
Eisho
E
Kosuga
Kunihiko
K
Hata
Tatsuhiko
T
Nakamura
Takuji
T
Fujita
Shinya
S
Takeda
Shinsaku
S
Motohara
Seiichiro
S
Uehata
Hiromu
H
D020341:Absorbable Implants; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D011091:Polyesters; D015607:Stents; D013552:Swine; D062367:ortho-Aminobenzoates / Q000008:administration & dosage*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010975:Platelet Aggregation Inhibitors; D011091:Polyesters; D062367:ortho-Aminobenzoates; C033616:poly(lactide); C012293:tranilast